Renal neoplasias in patients receiving dialysis and renal transplantation: Clinico-pathological features and p53 gene mutations

Transplantation

Volumn 68, Issue 3, 1999, Pages 385-390

  Hoshida, Yoshihiko ^a,c   Nakanishi, Hirofumi ^a   Shin, Masaru ^a   Satoh, Takaomi ^b   Hanai, Jun ^c   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIALYSIS; DISEASE PREDISPOSITION; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARCINOMA, RENAL CELL; CYCLOSPORINE; FEMALE; GENES, P53; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RENAL DIALYSIS; SEQUENCE ANALYSIS, DNA;

EID: 0033567220     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199908150-00010     Document Type: Article

References (40)

1. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prevent 1994; 18: 241.
2. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997; 71: 517.
3. Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosupressive drugs. Br Med J 1979; 2: 1461.
4. Hughson MD, Hennigar GR, McManus JFA. Atypical cysts, acquired renal cystic disease, and renal cell tumors in end stage dialysis kidneys. Lab Invest 1980; 42: 475.
5. Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 1977; 30: 868.
6. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993; 22: 135.
7. Ishikawa I. Renal cell carcinoma in chronic dialysis patients - a 1990 questionnaire study in Japan. Kidney Int 1993; 43: S167.
8. Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors. Morphologic, cytochemical, and genotypic features. Cancer 1995; 76: 669.
9. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (Chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997; 21: 621.
10. Kovacs G, Fuzesi L, Emanuel A, Kung H. Cytogenetic of papillary renal cell tumors. Genes Chrom Cancer 1991; 3: 249.
11. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology 1993; 22: 1.
12. Bugert P, Kovacs G. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 1996; 149: 2081.
13. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumor antigen to band 17p13. Nature 1986; 320: 84.
14. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453.
15. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49.
17. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM. 'Cold SSCP' : a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 1993; 21: 3637.
18. Hongyo T, Buzard GS, Palli D, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence. Cancer Res 1995; 55: 2665.
19. Kaplan EI, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
20. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1.
21. Scheffè H. The analysis of variance. New York: Wiley, 1959.
22. Mann HB, Whitney DR. On a test of whether one of two random variables is statistically larger than the other. Ann Math Statist 1947; 18: 50.
23. International Union Against Cancer (UICC). TNM classification of malignant tumors. In: Sobin LH, Wittekind CH eds. Urological tumors. New York: John Wiley & Sons 1997: 180.
24. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma. Cancer 1997; 80: 987.
25. Klintmalm GBG, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981; 1: 470.
26. Ishikawa I. Acquired cysts and neoplasms of the kidneys in renal allograft recipients. Contrib Nephrol 1992; 100: 254.
27. Ishikawa I, Saito Y, Onouchi Z, et al. Development of acquired cystic disease and adenocarcinoma of the kidney in glomerulonephritic chronic hemodialysis patients. Clin Nephrol 1980; 14: 1.
28. Ono K, Yasukohchi A, Kikawa K. Pathogenesis of acquired renal cysts in hemodialysis patients; the role of oxalate crystal deposition in renal tubules. Trans Am Soc Artif Intern Organs 1987; 33: 245.
29. Cohen EP, Elliott WC Jr. The role of ischemia in acquired cystic kidney disease. Am J Kidney Dis 1990; 15: 55.
30. Annotation. Acquired cystic disease of the kidney. Lancet 1977; 2: 1063.
31. Kirkwood RG, Dunn S, Thomasson L, Simenhoff ML. Generation of the precarcinogen dimethylnitrosamine (DMNA) in dialysate water. Trans Am Soc Artif Intern Organs 1981; 27: 168.
32. Torigoe S, Shuin T, Kubota, Y, Horikoshi T, Danenberg K, Danenberg PV. p53 gene mutation in primary human renal cell carcinoma. Oncol Res 1993; 4: 467.
33. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994; 7: 766.
34. Chemeris G, Loktinov A, Rempel A, Schwarz M, Bannasch P. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch 1995; 426: 563.
35. Kikuchi Y, Kishi T, Suzuki M, Furusato M, Aizawa S. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch 1994; 424: 229.
36. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res 1994; 54: 3682.
37. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995; 55: 658.
38. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317.
39. Shuin, T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54: 2852.
40. Darby CR, Cranston D, Raine AEG, Morris PJ. Bilateral nephrectomy before transplantation: indications, surgical approach, morbidity and mortality. Br J Surg 1991; 78: 305.